This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Dylan Morris
General Partner at CRV


Dylan Morris is a General Partner in CRV’s Bioengineering practice. He serves on the boards of Dyno Therapeutics, Deciduous Therapeutics, and Switch Therapeutics; and has led the firm’s investments in Recursion Pharmaceuticals, Exo Therapeutics, Plexium, and 3T Biosciences. He previously invested at Innovation Endeavors, an early-stage venture firm backed by Eric Schmidt, of Google/Alphabet. At IE, Dylan drove investments in companies operating at the intersection of computing and biology, including Freenome, a CRV portfolio company that applies deep learning to liquid biopsy for early cancer detection. Previously, he cofounded Integrated Plasmonics, a venture-backed point-of-care diagnostics startup. Dylan conducted graduate research in Biophysics at Caltech and received his A.B. in Computer Science from Harvard.

Agenda Sessions

  • Investment, Commercialization, and Value Recognition: The AI Healthcare Hurdle

    On Demand

Speakers at this event